Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS01-T in Relapsed or Refractory B Cell Malignancies
NCT01435720Phase 2Unknown
- Sponsor
- Senesco Technologies, Inc.
- Start
- Sep 2011
- Primary completion
- Oct 2014
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of SNS01-T in multiple myeloma (MM), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), plasma cell leukemia (PCL), sponsored by Senesco Technologies, Inc.. Status: unknown.
02
Drugs
SNS01-T
03
Conditions
multiple myeloma (MM)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT01435720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01435720.